• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Daiichi Sankyo - Articles and news items

Daiichi Sankyo enrols first patient in Phase III acute myeloid leukaemia trial

Industry news / 17 October 2016 / Niamh Louise Marriott, Digital Content Producer

Daiichi Sankyo has enrolled their first patient in the global phase 3 QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients…

Daiichi Sankyo Phase 1 HER2-targeting antibody drug safe and effective to treat breast cancer

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

DS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase…

Servier Canada to market edoxaban in Canada

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

Edoxaban is an oral anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting…

Phase III study of tivantinib in hepatocellular carcinoma continues

Industry news / 22 March 2016 / Victoria White

ArQule and Daiichi Sankyo today announced that the independent DMC has determined that the METIV-HCC will continue to its final analysis…


Daiichi Sankyo expands access to its clinical trial data

Industry news / 2 February 2016 / Victoria White

Daiichi Sankyo has announced that it will share its clinical trial data to qualified researchers through the clinicalstudydatarequest.com system…

SMC accepts Keytruda as a treatment option for advanced melanoma

Industry news / 10 November 2015 / Victoria White

The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)…

FDA grants Breakthrough Therapy Designation to pexidartinib for the treatment of TGCT

Industry news / 3 November 2015 / Victoria White

The Breakthrough Therapy Designation was granted based on results from an extension cohort of a Phase 1 study that assessed the safety and efficacy of pexidartinib…

Phase 3 study of CL-108 meets primary endpoints

Industry news / 30 October 2015 / Victoria White

CL-108 is being developed as a treatment for moderate to severe pain and the prevention of opioid-induced nausea and vomiting (OINV)…

World Stroke Day: Daiichi Sankyo highlights stroke risks associated with cardiovascular diseases

Industry news / 29 October 2015 / Victoria White

To mark its support for World Stroke Day, Daiichi Sankyo has initiated a campaign that highlights stroke risks associated with cardiovascular diseases…


Daiichi Sankyo reorganises its US commercial operations

Industry news / 19 October 2015 / Victoria White

Daiichi Sankyo has said that it will reorganise its US commercial operations from a maturing primary care product portfolio to a differentiated specialty portfolio…

Daiichi Sankyo helps raise awareness of VTE and AF

Industry news / 13 October 2015 / Daiichi Sankyo

Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms…

NICE recommends blood-thinning drug edoxaban

Industry news / 23 September 2015 / Victoria White

NICE has issued its final recommendation for edoxaban to help prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation…